CRRT for Glutamate Elimination After Cardiac Arrest

Not Applicable

Completed

• Conditions: Reperfusion Syndrome
• Interventions: Procedure: Continuous renal replacement therapy

• Registration Number: NCT02963298
• Lead Sponsor: C. Storm

Brief Summary

Glutamate is known to be a mediator for apoptosis after brain hypoxia e.g. due to cardiac arrest. This pilot trial evaluates the possibility of elimination of Glutamate by CRRT after cardiac arrest.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-10
• Study First Submitted: 2016-10-11
• Study First Submitted QC: 2016-11-10
• Study First Posted: 2016-11-15
• Primary Completion: 2017-09-06
• Study Completion: 2017-09-06
• Status Verified: 2019-06
• Last Update Submitted: 2019-06-20
• Last Update Posted: 2019-06-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

• post cardiac arrest

Exclusion Criteria

• hemodynamic instable
• in-hospital cardiac arrest

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CRRT after cardiac arrest	Continuous renal replacement therapy	Continuous renal replacement therapy (CRRT) after cardiac arrest for 72 hours for elimination of Glutamate. Repetitive testing of blood Glutamate levels.

Primary Outcome Measures

Name	Time	Method
Glutamate blood concentration in intervention arm over the time	72 hours	Reduction of blood Glutamate concentration by renal replacement therapy

Secondary Outcome Measures

Name	Time	Method
number of participants with abnormal outcome parameters	up to 14 days

Trial Locations

Locations (1)

Charité-Universitätsmedizin Berlin; 🇩🇪 Berlin, Germany